PTEN-mediated ERK1/2 Inhibition and Paradoxical Cellular Proliferation Following Pnck Overexpression
Overview
Authors
Affiliations
Pregnancy upregulated non-ubiquitous calmodulin kinase (Pnck), a novel calmodulin kinase, is significantly overexpressed in breast and renal cancers. We present evidence that at high cell density, overexpression of Pnck in HEK 293 cells inhibits serum-induced extracellular signal-regulated kinase (ERK1/ERK2) activation. ERK1/2 inhibition is calcium-dependent and Pnck kinase activity is required for ERK1/2 inhibition, since expression of a kinase-dead (K44A) and a catalytic loop phosphorylation mutant (T171A) Pnck protein is unable to inhibit ERK1/2 activity. Ras is constitutively active at high cell density, and Pnck does not alter Ras activation, suggesting that Pnck inhibition of ERK1/2 activity is independent of Ras activity. Pnck inhibition of serum-induced ERK1/2 activity is lost in cells in which phosphatase and tensin homolog (PTEN) is suppressed, suggesting that Pnck inhibition of ERK1/2 activity is mediated by PTEN. Overexpression of protein phosphatase-active but lipid phosphatase-dead PTEN protein inhibits ERK1/2 activity in control cells and enhances Pnck-mediated ERK1/2 inhibition, suggesting that Pnck increases availability of protein phosphatase active PTEN for ERK1/2 inhibition. Pnck is a stress-responsive kinase; however, serum-induced p38 MAP kinase activity is also downregulated by Pnck in a Pnck kinase- and PTEN-dependent manner, similar to ERK1/2 inhibition. Pnck overexpression increases proliferation, which is inhibited by PTEN knockdown, implying that PTEN acts as a paradoxical promoter of proliferation in ERK1/2 and p38 MAP kinase phosphorylation-inhibited, Pnck-overexpressing cells. Overall, these data reveal a novel function of Pnck in the regulation of ERK1/2 and p38 MAP kinase activity and cell proliferation, which is mediated by paradoxical PTEN functions. The possible biological implications of these data are discussed.
Hu D, Zhang Z, Liu X, Wu Y, An Y, Wang W J Transl Med. 2024; 22(1):512.
PMID: 38807223 PMC: 11134716. DOI: 10.1186/s12967-024-05326-0.
Tumor Suppressors Having Oncogenic Functions: The Double Agents.
Datta N, Chakraborty S, Basu M, Ghosh M Cells. 2021; 10(1).
PMID: 33396222 PMC: 7824251. DOI: 10.3390/cells10010046.
MiR-132 controls pancreatic beta cell proliferation and survival through Pten/Akt/Foxo3 signaling.
Mziaut H, Henniger G, Ganss K, Hempel S, Wolk S, McChord J Mol Metab. 2020; 31:150-162.
PMID: 31918917 PMC: 6928290. DOI: 10.1016/j.molmet.2019.11.012.
Xu Y, Wang J, Cai S, Chen G, Xiao N, Fu Y J Cancer. 2019; 10(27):6925-6932.
PMID: 31839828 PMC: 6909947. DOI: 10.7150/jca.33698.